Skip to content

​The effectiveness of a mindfulness-based cognitive therapy programme for preventing relapse in patients with depression

Kanokwan Wongkhueng, Kedsaraporn Kenbubpha, Palida Phalasak, Thawatchai Phalasak, Plubplung Hasook

Research Square October 11, 2026 preprint DOI: 10.21203/rs.3.rs-10890753/v1 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial
Sample size 94
Population Thai inpatients with moderate to severe ICD-10 depressive disorder at a psychiatric hospital
Duration Six group sessions of 60–90 minutes over three weeks; assessments before and after the intervention and at three months; readmission recorded within three months of discharge
Measures 9Q, RRS, MAS
Topics Depression Meditation
Key findings Brief, nurse-led, culturally adapted MBCT added clinically meaningful benefit to routine inpatient care, sustained to three months, with larger reductions in depressive symptoms and rumination and greater increases in mindfulness than routine care alone. Minimal-symptom status was reached by 51.1% of MBCT participants versus 2.1% of controls (number needed to treat 2.0). Readmission was less frequent under MBCT (2 of 47 versus 7 of 47) but not significantly so, and the trial was underpowered for readmission.

Abstract

Abstract Objectives Mindfulness-based cognitive therapy (MBCT) has rarely been tested in non-Western inpatient services or delivered by nurses. This trial evaluated a culturally adapted, nurse-led group MBCT programme for Thai inpatients.

Method: Ninety-four inpatients with moderate to severe ICD-10 depressive disorder at a Thai psychiatric hospital were randomised 1:1 to MBCT plus routine nursing care or routine care alone. The programme comprised six group sessions of 60–90 minutes over three weeks. Depressive symptoms (9Q), rumination (RRS) and mindfulness (MAS) were assessed before and after the intervention and at three months; readmission within three months of discharge was recorded. Sixteen completers took part in two focus groups (content analysis).

Results: The arms were equivalent at baseline. Time × Group interactions favoured MBCT on all three outcomes (all p < .001; partial η² = .13–.40). Both arms improved, but at three months MBCT showed lower depressive symptoms (mean difference 3.49, 95% CI [2.75, 4.23], d = 1.93), lower rumination ( d = 3.34) and higher mindfulness ( d = 2.16). Rumination gains were fully maintained after discharge ( p = 1.000) whereas controls deteriorated; mindfulness eroded partially in both arms. Minimal-symptom status was reached by 51.1% of MBCT participants versus 2.1% of controls ( p < .001), a number needed to treat of 2.0. Readmission was less frequent under MBCT (2 of 47 versus 7 of 47) but not significantly so (Fisher's exact p = .158). Three themes emerged: recognising emotions and automatic thoughts; behavioural change with self-compassion; and stress management for relapse prevention.

Conclusions: Brief, nurse-led, culturally adapted MBCT added clinically meaningful benefit to routine inpatient care, sustained to three months. The trial was underpowered for readmission. Partial erosion of mindfulness gains suggests booster contact may be needed. Preregistration TCTR20250927009, Registration date: September 27, 2025

Comparable studies

Other randomized controlled trials on depression, most cited first.

Study Year Design Participants
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Subjects with DSM-IV major depression (treatment resistant) 2006 Randomized, placebo-controlled, double-blind crossover study n = 18
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. Recovered recurrently depressed patients 2004 Randomized controlled trial n = 73

Citations in the library

Explore topics